Ulcerative Colitis and Probiotics: an Overview

Total Page:16

File Type:pdf, Size:1020Kb

Ulcerative Colitis and Probiotics: an Overview REVIEW Ulcerative colitis and probiotics: An overview Irfan Ahmad Rather1, Rajib Majumder1, Fanar Hamad Alshammari1, Jae Gyu Park2 and Vivek Kumar Bajpai1* 1Department of Applied Microbiology and Biotechnology, School of Biotechnology, Yeungnam University, Gyeongsan, Gyeongbuk, Korea 2Pohang Technopark, Pohang Center for Evaluation of Biomaterials, Jigok-ro, Nam-gu, Pohang, Gyeongbuk, Korea Abstract: Ulcerative colitis is an inflammatory disease of the large intestine whose effects are bloody diarrhea, cramping and bloating. The disease is usually relapsing and remitting. However, the cause of ulcerative colitis is not yet known. Due to this reason, finding an effective treatment has been a great challenge. The suggested medical treatment is usually composed of two portions; keeping the flare up from happening and treating the flare up when it has happened. Active flare ups are treated with corticosteroids. There are several hypothesis which suggest that ulcerative colitis could be due to the micro flora present in gut. For this reason, several researchers tried to modify the gut microflora with probiotics. However, there is no probiotics found that can induce emission faster than the placebo. The ulcerative colitis patients taking probiotics showed fewer and less severe symptoms during the flare up. This means that even though the probiotics did not end up the flare up faster, it slowed up the severity of the symptoms of the patients. Keywords: Ulcerative colitis, inflammation, probiotics. INTRODUCTION important in digestion and also prevent other types of bacteria from occupying their spaces. This is the basic Ulcerative colitis (UC) is a chronic disease which is concept of the probiotics referred to as the good bacteria. characterized by diffuse inflammation of rectal and These probiotics work in different ways. First they act as colonic mucosa (Tannis 2008). The disease mainly affects barriers lining the intestinal tract where through the rectum, but extends to some parts of the large competition inhibition, they are able to prevent other intestines. The most conspicuous classical clinical sign of laminal bacteria from reaching the lamina propria and this disease is bloody diarrhea from the patients, and the stimulate mucosal immune system (Tannis 2008). The clinical course sign is a period of remission and second mechanism is by enhancing mucus production so exacerbation. The incidence of this disease has rapidly that patients have a thicker mucus layer which is increased in the developing nations (Tannis 2008). Many important in preventing invasion by bacteria. Probiotics reports confirm that there is an interaction between are responsible in altering the consistency of mucus hence genetic and environmental factors in the etiology of the changing the bacteria adherence pattern (Kabelitz 2005). disease (Potter 2004). In order to reduce mortality and The probiotics also aid in production of protective deaths, patients with this disease should be identified and immunoglobulins and protective defensins and treated early. (Potter 2004). There are many types of bacteriosins into the body lumen (Baumgart 2012). In medication available to treat mild to severe forms of UC. addition, probiotics help in altering the function of The goal of each medication is to maintain remission and mucosal immune system making it less inflammatory improve the quality of life. However, one of the serious (Lichtenstein 2014). However, it is still early to conclude concerns of all these medications is their adverse side if probiotics would be an alternative treatment for UC. effects. Therefore, finding new alternative treatments for UC have been always a new challenge. It believed that Epidemiology of ulcerative colitis UC could be due to complex interactions of gut Ulcerative colitis is the most common type of microbiome. Therefore, in past years many researchers try inflammatory disease of the bowel. In the United to modify the gut microflora with probiotics. The human Kingdom, its incidence is approximately 10 per 100,000 gastrointestinal tract is usually covered with bacteria. people per year (Wallace 2008), and prevalence is Most of the bacteria are harmless; however, some are approximated to be about 240 per 100,000 (Singleton harmful and causes infection that leads to persistent 2009). UC can develop to anybody at any age; but, its intestinal dysbiosis (Janeway et al., 2001; Parfenov and incidence peaks at the age of between 15 and 25 years, Ruchkina 2011). The bacteria in the intestines are and also between 55 and 65 years. The effects of UC are seen in both men and women equally (Wallace 2008). In *Corresponding author: e-mail: [email protected] the United State, more than 200 per every 100,000 people Pak. J. Pharm. Sci., Vol.29, No.5(Suppl), September 2016, pp.1877-1880 1877 Ulcerative colitis and probiotics: An overview are usually affected by this disease and is higher in whites Current treatment of ulcerative colitis and the Ashkenazi. Worldwide, this disease is mostly It has been seen that patients with mild to moderate distal concentrated in Europe, North America and Australia. The or left sided colitis, therapy includes oral or topical effects of this disease have increased in the developed mesalamine (5-ASA) agents or both (Baumgart 2012). countries (Singleton 2009). However, there is a difference The combination of two is more active than neither alone. in the incidence and prevalence of the disease in these This therapy maintains UC and remission and superior to regions. The incidence rate ranges from 0.5 to 31.5 per corticosteroids for distal disease. Steroid enemas are used 100, 000 people while the prevalence rate ranges from 5.3 for the active diseases; but, cannot be used in maintaining to 63.6 per 100,000 people annually (Lichtenstein 2014). remission (Kabelitz 2005). Some of the medications used This range is however higher in North America where it for these kind of patients are; sulfasalazine, olsalazine, ranges from 37.5 to 238 per 100, 00 people (Singleton balsalazide, mesalamine (pentasa, asacol, asacol HD, 2009); however, in South America the prevalence is less. liada, apriso) mesalamine suppository and mesalamine A study conducted in Puerto Rico show that the rectal suspension (Potter 2004). In addition, there are prevalence of the UC is 12.3per 100, 000 people while it number of new drugs of UC in pipeline (Table 1) and is 14.81 per 100,000 people in Brazil (Wallace 2008). many drugs have been stopped after clinical trials due to poor results. Mortality rate of people with UC was high in the first half of the twentieth century; but, currently it has greatly Probiotics for ulcerative colitis reduced due to the usage of corticosteroids and It is still assumed that UC is caused by integrative factors, sulfasalazine (Sutherland et al., 2014). Surgical such as genetic susceptibility which is an imbalance techniques have also been of great help in reducing between gastrointestinal probiotics and pathogens, an mortality rate. However, mortality rate due to UC is impairment of intestinal epithelial cells and host immune higher than the rate in the general population (Sutherland dysfunctions (Rutgeerts 1999). The human intestinal tract et al., 2014). plays host to approximately 100 trillion microorganisms, with at least 15,000-36,000 bacterial species. The The disease is more common in smokers than the intestinal microbiota is now considered to be a functional nonsmokers. It mostly affects people in the urban areas organ associated with normal physiological processes, compared to those in rural regions. This means that such as metabolism, immunological response and urbanization is a contributing factor to this infection intestinal epithelium morphogenesis. Thus, there are (Potter 2004). This is as a result of westernization of many areas of host health that can be compromised when lifestyle like change of diet, smoking, industrial the microbiota is drastically altered. Many probiotics are chemicals, pollution and difference in exposure to effective as traditional ulcerative medications like the sunlight (Martin et al., 2014). UC is more prevalent to gold-standard treatment mesalamine and have been people with white collar jobs (Wallace 2008). Many reported both had the same effects on the patients (Jewell reports showed that the use of oral contraceptives, et al., 2006). Recently, it was reported that probiotics perinatal and child infections, a typical mycobacteria suppress colitis-associated carcinogenesis (Do et al, infections among others were the other factors that 2015). However, these probiotics can influence the affected the rate of spread of the UC (Martin et al., 2014). activity of the immune cells and the cells that lines the intestines. The intestinal flora dysbacteriosis contributes Risk factors of ulcerative colitis to the pathogenesis of UC. Probiotics are nonpathogenic Genetic factors: Ulcerative disease can be hereditary. beneficial flora, which have important effects on Therefore, patient’s family or relatives could be at a maintaining the balance of intestinal flora (Onderdonk high risk of being infected. 2000). Probiotics can adjust the metabolic activity of the Environmental factors: Environmental changes such as intestinal flora and their components by preventing exposure of body with pollen, bacteria and chemicals bacterial overgrowth and by maintaining the integrity of could result in uncontrolled inflammation of the intestinal mucosal barrier, thereby adjusting and gastrointestinal tract.
Recommended publications
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
    bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
    [Show full text]
  • Immunfarmakológia Immunfarmakológia
    Gergely: Immunfarmakológia Immunfarmakológia Prof Gergely Péter Az immunpatológiai betegségek döntő többsége gyulladásos, és ennek következtében általában szövetpusztulással járó betegség, melyben – jelenleg – a terápia alapvetően a gyulladás csökkentésére és/vagy megszűntetésére irányul. Vannak kizárólag gyulladásgátló gyógyszereink és vannak olyanok, amelyek az immunreakció(k) bénításával (=immunszuppresszió révén) vagy emellett vezetnek a gyulladás mérsékléséhez. Mind szerkezetileg, mind hatástanilag igen sokféle csoportba oszthatók, az alábbi felosztás elsősorban didaktikus célokat szolgál. 1. Nem-szteroid gyulladásgátlók (‘nonsteroidal antiinflammatory drugs’ NSAID) 2. Kortikoszteroidok 3. Allergia-elleni szerek (antiallergikumok) 4. Sejtoszlás-gátlók (citosztatikumok) 5. Nem citosztatikus hatású immunszuppresszív szerek 6. Egyéb gyulladásgátlók és immunmoduláns szerek 7. Biológiai terápia 1. Nem-szteroid gyulladásgátlók (NSAID) Ezeket a vegyületeket, melyek őse a szalicilsav (jelenleg, mint acetilszalicilsav ‘aszpirin’ használatos), igen kiterjedten alkalmazzák a reumatológiában, az onkológiában és az orvostudomány szinte minden ágában, ahol fájdalom- és lázcsillapításra van szükség. Egyes felmérések szerint a betegek egy ötöde szed valamilyen NSAID készítményt. Szerkezetük alapján a készítményeket több csoportba sorolhatjuk: szalicilátok (pl. acetilszalicilsav) pyrazolidinek (pl. fenilbutazon) ecetsav származékok (pl. indometacin) fenoxiecetsav származékok (pl. diclofenac, aceclofenac)) oxicamok (pl. piroxicam, meloxicam) propionsav
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021
    Lääkealan turvallisuus- ja kehittämiskeskus Säkerhets- och utvecklingscentret för läkemedelsområdet Finnish Medicines Agency Lääkeaineiden yleisnimet (INN-nimet) 21.6.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Bristol-Myers Squibb Company – Product Pipeline Review – 2014
    Bristol-Myers Squibb Company – Product Pipeline Review – 2014 Reference Code: GMDHC05245CDB Publication Date: JUN 2014 Bristol-Myers Squibb Company – Product Pipeline Review – 2014 GMDHC05245CDB/ Published JUN 2014 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Bristol-Myers Squibb Company – Product Pipeline Review Table of Contents Table of Contents ....................................................................................................................................................................... 2 List of Tables ....................................................................................................................................................................... 12 List of Figures ...................................................................................................................................................................... 12 Bristol-Myers Squibb Company Snapshot.................................................................................................................................. 13 Bristol-Myers Squibb Company Overview ............................................................................................................................. 13 Key Information ................................................................................................................................................................... 13 Key Facts ...........................................................................................................................................................................
    [Show full text]
  • Anti-Integrin Therapy for Inflammatory Bowel Disease S
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Hofstra Northwell Academic Works (Hofstra Northwell School of Medicine) Donald and Barbara Zucker School of Medicine Journal Articles Academic Works 2018 Anti-integrin therapy for inflammatory bowel disease S. C. Park Zucker School of Medicine at Hofstra/Northwell Y. T. Jeen Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles Part of the Ophthalmology Commons Recommended Citation Park SC, Jeen YT. Anti-integrin therapy for inflammatory bowel disease. 2018 Jan 01; 24(17):Article 3452 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/3452. Free full text article. This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more information, please contact [email protected]. Submit a Manuscript: http://www.f6publishing.com World J Gastroenterol 2018 May 7; 24(17): 1868-1880 DOI: 10.3748/wjg.v24.i17.1868 ISSN 1007-9327 (print) ISSN 2219-2840 (online) MINIREVIEWS Anti-integrin therapy for inflammatory bowel disease Sung Chul Park, Yoon Tae Jeen Sung Chul Park, Division of Gastroenterology and Hepatology, Abstract Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon 24289, South Korea In inflammatory bowel disease (IBD), tumor necro­ sis factor plays an important role in mediating infla­ Yoon Tae Jeen, Division of Gastroenterology and Hepatology, mmation, but several other pathways are also involved Department of Internal Medicine, Korea University Anam Hospital, in eliciting an inflammatory response.
    [Show full text]
  • Biological Treatments in Inflammatory Bowel Disease: a Complex Mix Of
    Review Biological Treatments in Inflammatory Bowel Disease: A Complex Mix of Mechanisms and Actions Lorena Ortega Moreno 1,2,3 , Samuel Fernández-Tomé 1,3 and Raquel Abalo 4,5,6,7,* 1 Instituto de Investigación Sanitaria Hospital Universitario de La Princesa, 28006 Madrid, Spain; [email protected] (L.O.M.); [email protected] (S.F.-T.) 2 Department of Medicine, Faculty of Medicine, Universidad Autónoma de Madrid, 28049 Madrid, Spain 3 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 28029 Madrid, Spain 4 Department of Basic Health Sciences, Faculty of Health Sciences, University Rey Juan Carlos (URJC), 28922 Alcorcón, Spain 5 High Performance Research Group in Physiopathology and Pharmacology of the Digestive System (NeuGut-URJC), URJC, 28922 Alcorcón, Spain 6 Associated I+D+i Unit to the Institute of Medicinal Chemistry (IQM), Scientific Research Superior Council (CSIC), 28006 Madrid, Spain 7 Working Group of Basic Sciences in Pain and Analgesia of the Spanish Pain Society (Grupo de Trabajo de Ciencias Básicas en Dolor y Analgesia de la Sociedad Española del Dolor), 28046 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-91-488-8854 Abstract: Inflammatory bowel disease (IBD) is a chronic disease that requires lifelong medication and whose incidence is increasing over the world. There is currently no cure for IBD, and the current ther- apeutic objective is to control the inflammatory process. Approximately one third of treated patients do not respond to treatment and refractoriness to treatment is common. Therefore, pharmacological Citation: Moreno, L.O.; treatments, such as monoclonal antibodies, are urgently needed, and new treatment guidelines are Fernández-Tomé, S.; Abalo, R.
    [Show full text]